Posts Tagged ‘prostate cancer support’

Prostate Cancer: Is Active Surveillance an Option?

guys (1)For many years, most men with prostate cancer were given the option of either surgery or radiation. Over time, doctors saw many men had prostate cancer that was less aggressive and unlikely to spread to other parts of the body or shorten lifespan. Doctors were also learning that many of these men were experiencing the downsides of prostate cancer treatment (e.g. difficulty with erections, leakage of urine) without benefit.

In response to “over treatment”, some centers offered men with low-risk prostate cancer prognosis were enrolled in a clinical trial of “active surveillance”. After 15 years of follow-up, half of the patients were able to avoid prostate cancer treatment. Today, these studies—with nearly 20 years follow-up—show excellent results of active surveillance for low-risk prostate cancer.

Men with low prostate-specific antigen (PSA) test results, low-grade tumors, and minimal abnormalities on the prostate exam are considered for the newer protocols. Active surveillance programs usually involve repeat biopsies every one to two years and PSA tests every three to six months. Treatment is recommended if the patient is found to have higher-risk disease.

It is difficult to hear a cancer diagnosis and then be presented with surveillance as an option to avoid treatment. Yet, cancer patients can trust that active surveillance is a process that can delay or avoid cancer treatment side effects with rare risk of death from prostate cancer. Newer technologies, like multiparametric magnetic-resonance imaging and molecular biomarkers, may identify more prostate cancer patients who would benefit from active surveillance.

In the end, among selected patients on active surveillance, death or progression of cancer is rare. There is no evidence that prostate cancer patients who undergo delayed prostate cancer treatment fare worse than those treated immediately. In fact, they avoid the side effects of cancer treatment over that time. If newly diagnosed with prostate cancer, active surveillance may be an option worth discussing with your urologist or radiation oncologist.

Additional Resource:
The Prostate Cancer Support Group meets the 1st Wednesday of every month from 11:00 AM – 12:30 PM at the Clifton Campus. If you’re interested in further details visit: https://winshipcancer.emory.edu/about-us/events/

RELATED RESOURCES:
Cancer Clinical Study Leads to Video Tool for Prostate Cancer Patients
Two Patients Benefit from Two Alternative Treatment Options for Prostate Cancer
PSA Screening for Prostate Cancer – A Healthy Debate
Questions on Validity of PSA Test as Prostate Cancer Screening Tool
Prostate Cancer, To Screen or Not?
Winship’s Approach to Prostate Cancer Treatment

About Dr. Filson

filsonChristopher Filson, MD, MS, is an assistant professor of urology at Emory University School of Medicine. Dr. Filson started practicing with Emory Healthcare in July 2015. His main clinical specialties include robotic surgery, laparoscopic surgery, cystectomy, urinary diversion, prostatectomy and nephrectomy. Dr. Filson received his Medical Degree from University of Michigan in Ann Arbor MI. His postdoctoral training included a surgery internship and urology residency also at University of Michigan and a Fellowship in Urologic Oncology at University of California Los Angeles.

Cancer Clinical Study Leads to Video Tool for Prostate Cancer Patients

At Emory, research plays a key role in the mission to serve our patients and their families. Medical advances and improvements to patient care have been made possible by research and volunteer participation in clinical trials. More than 1,000 clinical trials are offered at Emory, making a difference in people’s lives, today.

Recently, a clinical study initiated by Winship Cancer Institute of Emory University, found that providing prostate cancer patients with a video-based education tool significantly improved their understanding of key terms necessary to making decisions about their treatment.

The breakthrough study was led by three Winship at Emory investigators; Viraj Master, MD, PhD, FACS; Ashesh Jani, MD; and Michael Goodman, MD, MPH; and is the feature cover story of this month’s Cancer, the peer-reviewed journal of the American Cancer Society.

In 2013, Master, Jani and Goodman released an Emory study that showed that prostate cancer patients (treated at Grady Hospital in Atlanta) experienced a severe lack of understanding of prostate key terms. The original study showed only 15 percent of the patients understood the meaning of “incontinence”; less than a third understood “urinary function” and “bowel habits”; and fewer than 50 percent understood the word “impotence.”

In response to their findings, the three principle investigators jumped to find a solution to the problem. The latest study explored using a video-based tool to educate prostate cancer patients on key terminology. The physicians predicted that with a better understanding of terms linked to disease, patients would be able to participate in shared and informed decision-making throughout the prostate cancer treatment process.

About the Prostate Cancer Video Trial:

  • 56 male patients were recruited from two low-income safety net clinics and received a key term comprehension test before and after viewing the educational video.
  • The video software (viewed by participants on iPads) featured narrated animations depicting 26 terms that doctors and medical staff frequently use in talking with prostate cancer patients.
  • Learn more by watching this video:

clinical trials for prostate cancer

Results of the Prostate Cancer Video Trial:

Participants who viewed the educational video demonstrated statistically significant improvements in comprehension of prostate terminology. For instance, before viewing the application, 14 percent of the men understood “incontinence”; afterward, 50 percent of them demonstrated understanding of the term.

“This shows that video tools can help patients understand these critical prostate health terms in a meaningful way. The ultimate goal is to give patients a vocabulary toolkit to further enable them to make shared and informed decisions about their treatment options,” says Viraj Master. “Our next goal is to improve the tool further, and study this tool at different centers.”

Learn more about clinical trials at Emory >>

Find a clinical trial at Emory >>

 

Additional Information about the Prostate Cancer Trial:

The research for this study was made possible by a Winship Cancer Institute multi-investigator pilot grant and the contributions of faculty and students from Winship, the Rollins School of Public Health and the Emory School of Medicine.

This study was led by three Winship at Emory investigators: Viraj Master, MD, PhD, FACS, Winship urologist and director of clinical research in the Department of Urology at Emory University; Ashesh Jani, MD, professor of radiation oncology in the Emory School of Medicine; and Michael Goodman, MD, MPH, associate professor of epidemiology with the Rollins School of Public Health.

Related Resources: